Antagonists of PD-1 and PD-L1 in Cancer Treatment

The PD-1 pathway, comprising the immune cell co-receptor Programmed Death 1 (PD-1) and its ligands, PD-L1 (B7-H1) and PD-L2 (B7-DC), mediates local immunosuppression in the tumor microenvironment. Drugs designed to block PD-1 or PD-L1 "release the brakes" on anti-tumor immunity and have de...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Seminars in oncology Ročník 42; číslo 4; s. 587 - 600
Hlavní autoři: Lipson, Evan J, Forde, Patrick M, Hammers, Hans-Joerg, Emens, Leisha A, Taube, Janis M, Topalian, Suzanne L
Médium: Journal Article
Jazyk:angličtina
Vydáno: United States 01.08.2015
Témata:
Antineoplastic Agents - therapeutic use
B7-H1 Antigen - antagonists & inhibitors
Biomarkers, Tumor - metabolism
Humans
Immunosuppression - methods
Neoplasms - drug therapy
Neoplasms - metabolism
Programmed Cell Death 1 Receptor - antagonists & inhibitors
Tumor Microenvironment - drug effects
ISSN:1532-8708
On-line přístup:Zjistit podrobnosti o přístupu
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Abstract The PD-1 pathway, comprising the immune cell co-receptor Programmed Death 1 (PD-1) and its ligands, PD-L1 (B7-H1) and PD-L2 (B7-DC), mediates local immunosuppression in the tumor microenvironment. Drugs designed to block PD-1 or PD-L1 "release the brakes" on anti-tumor immunity and have demonstrated clinical activity in several types of advanced cancers, validating this pathway as a target for cancer therapy. Two such drugs have recently been approved to treat melanoma and lung cancers, and regulatory approvals in first- and second-line settings for additional cancer types are anticipated. The manageable safety profile of PD-1/PD-L1 blocking drugs identifies them as suitable for outpatient administration and the development of combinatorial therapies. Ongoing studies aim to identify biomarkers to guide patient selection, which would further improve the risk:benefit ratio for these drugs.
AbstractList The PD-1 pathway, comprising the immune cell co-receptor Programmed Death 1 (PD-1) and its ligands, PD-L1 (B7-H1) and PD-L2 (B7-DC), mediates local immunosuppression in the tumor microenvironment. Drugs designed to block PD-1 or PD-L1 "release the brakes" on anti-tumor immunity and have demonstrated clinical activity in several types of advanced cancers, validating this pathway as a target for cancer therapy. Two such drugs have recently been approved to treat melanoma and lung cancers, and regulatory approvals in first- and second-line settings for additional cancer types are anticipated. The manageable safety profile of PD-1/PD-L1 blocking drugs identifies them as suitable for outpatient administration and the development of combinatorial therapies. Ongoing studies aim to identify biomarkers to guide patient selection, which would further improve the risk:benefit ratio for these drugs.
Author Forde, Patrick M
Emens, Leisha A
Hammers, Hans-Joerg
Taube, Janis M
Lipson, Evan J
Topalian, Suzanne L
Author_xml – sequence: 1
  givenname: Evan J
  surname: Lipson
  fullname: Lipson, Evan J
  organization: Department of Oncology, The Johns Hopkins University School of Medicine and Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD
– sequence: 2
  givenname: Patrick M
  surname: Forde
  fullname: Forde, Patrick M
  organization: Department of Oncology, The Johns Hopkins University School of Medicine and Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD
– sequence: 3
  givenname: Hans-Joerg
  surname: Hammers
  fullname: Hammers, Hans-Joerg
  organization: Department of Oncology, The Johns Hopkins University School of Medicine and Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD
– sequence: 4
  givenname: Leisha A
  surname: Emens
  fullname: Emens, Leisha A
  organization: Department of Oncology, The Johns Hopkins University School of Medicine and Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD
– sequence: 5
  givenname: Janis M
  surname: Taube
  fullname: Taube, Janis M
  organization: Department of Oncology, The Johns Hopkins University School of Medicine and Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD; Department of Dermatology, The Johns Hopkins University School of Medicine and Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD; Department of Pathology, The Johns Hopkins University School of Medicine and Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD
– sequence: 6
  givenname: Suzanne L
  surname: Topalian
  fullname: Topalian, Suzanne L
  organization: Department of Surgery, The Johns Hopkins University School of Medicine and Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD
BackLink https://www.ncbi.nlm.nih.gov/pubmed/26320063$$D View this record in MEDLINE/PubMed
BookMark eNo1j1tLxDAUhIMo7kX_guTRl9ack0u7j0t1VSgouO8lTU-lS5uuTfbBf2_FFQZmGD4GZsUu_eiJMQ4iBaHlwyENNHRz6cY-RQE6FbNAXrAlaIlJnol8wVYhHIRAyBCv2QKNRCGMXDLY-mg_R9-FGPjY8vfHBLj1zW8ogXeeF9Y7mvh-IhsH8vGGXbW2D3R79jX72D3ti5ekfHt-LbZl4ozOYqLICNJEBkVTo1KSCJTNG0IiEhKImo1SDqBBMlraNne6xTZTjuoccM3u_1aP0_h1ohCroQuO-t56Gk-hgvlVvjFK6hm9O6OneqCmOk7dYKfv6v8k_gBxY1UA
CitedBy_id crossref_primary_10_1080_08830185_2020_1775827
crossref_primary_10_1155_2023_2736932
crossref_primary_10_1007_s00335_018_9763_6
crossref_primary_10_1186_s13550_017_0303_2
crossref_primary_10_3389_fphar_2020_593247
crossref_primary_10_1038_s41571_018_0003_5
crossref_primary_10_1016_j_clbc_2018_05_006
crossref_primary_10_3389_fonc_2021_693542
crossref_primary_10_1016_j_lungcan_2022_03_019
crossref_primary_10_1016_j_jtbi_2020_110250
crossref_primary_10_1097_MD_0000000000025715
crossref_primary_10_3390_ijms19082413
crossref_primary_10_1016_j_nucmedbio_2020_07_006
crossref_primary_10_1038_onc_2017_188
crossref_primary_10_1002_cjp2_135
crossref_primary_10_1111_liv_13746
crossref_primary_10_1158_2326_6066_CIR_21_0369
crossref_primary_10_1158_1078_0432_CCR_22_1987
crossref_primary_10_3390_jcm9010286
crossref_primary_10_1007_s13273_023_00351_4
crossref_primary_10_1080_14737140_2022_2023011
crossref_primary_10_1158_1078_0432_CCR_16_3063
crossref_primary_10_3762_bjoc_20_162
crossref_primary_10_1097_PAI_0000000000000575
crossref_primary_10_1080_2162402X_2018_1532764
crossref_primary_10_3390_cancers14102499
crossref_primary_10_1007_s10689_016_9884_6
crossref_primary_10_1016_j_medcli_2020_06_057
crossref_primary_10_1016_j_ymthe_2022_07_022
crossref_primary_10_1007_s10989_021_10289_7
crossref_primary_10_1007_s00262_019_02416_7
crossref_primary_10_1016_j_canlet_2020_12_012
crossref_primary_10_1136_jitc_2020_001156
crossref_primary_10_1111_liv_14489
crossref_primary_10_1016_j_biomaterials_2022_121899
crossref_primary_10_1080_2162402X_2016_1235107
crossref_primary_10_1016_j_oraloncology_2016_08_001
crossref_primary_10_3389_fimmu_2023_1173518
crossref_primary_10_1186_s12915_020_00765_9
crossref_primary_10_1042_BSR20202898
crossref_primary_10_1111_ddg_12891
crossref_primary_10_1111_cas_12861
crossref_primary_10_1186_s13058_024_01810_z
crossref_primary_10_2217_epi_2018_0149
crossref_primary_10_3390_cancers14235820
crossref_primary_10_3389_fonc_2022_824166
crossref_primary_10_18632_oncotarget_17397
crossref_primary_10_1002_btm2_10716
crossref_primary_10_1186_s40425_017_0228_3
crossref_primary_10_1080_14712598_2017_1256388
crossref_primary_10_1080_14737140_2018_1417845
crossref_primary_10_1016_j_molmed_2016_05_004
crossref_primary_10_1158_1078_0432_CCR_16_2848
crossref_primary_10_2147_CMAR_S263010
crossref_primary_10_1155_2022_4635806
crossref_primary_10_1016_j_intimp_2023_111128
crossref_primary_10_1208_s12248_019_0333_y
crossref_primary_10_1007_s12312_017_0249_3
crossref_primary_10_1186_s41231_019_0032_9
crossref_primary_10_1111_iju_70023
crossref_primary_10_1016_j_ejca_2017_09_026
crossref_primary_10_3390_antib8010003
crossref_primary_10_1007_s00262_021_03042_y
crossref_primary_10_3390_life13051189
crossref_primary_10_4049_jimmunol_2300067
crossref_primary_10_3389_fsurg_2016_00011
crossref_primary_10_3389_fimmu_2017_00650
crossref_primary_10_1016_j_smim_2020_101425
crossref_primary_10_1016_j_tranon_2023_101678
crossref_primary_10_1097_MD_0000000000008242
crossref_primary_10_1007_s40005_018_0399_z
crossref_primary_10_1007_s13205_025_04362_x
crossref_primary_10_1016_j_coi_2016_01_002
crossref_primary_10_1016_j_ejca_2017_01_035
crossref_primary_10_1016_j_jconrel_2022_09_027
crossref_primary_10_1080_14737140_2019_1699407
crossref_primary_10_3390_ijms21124427
crossref_primary_10_1158_1078_0432_CCR_16_3001
crossref_primary_10_3390_cancers13205049
crossref_primary_10_1158_2326_6066_CIR_15_0064
crossref_primary_10_1016_j_surg_2018_06_013
crossref_primary_10_1111_jcmm_18524
crossref_primary_10_3390_cancers10120494
crossref_primary_10_1038_nrc_2016_36
crossref_primary_10_1186_s13046_017_0541_1
crossref_primary_10_1080_14728222_2021_1869212
crossref_primary_10_1097_MD_0000000000025008
crossref_primary_10_2217_imt_2016_0039
crossref_primary_10_1097_MCP_0000000000000382
crossref_primary_10_1158_0008_5472_CAN_16_0274
crossref_primary_10_1177_1753465817750075
crossref_primary_10_1080_14712598_2018_1469619
crossref_primary_10_12688_f1000research_16627_1
crossref_primary_10_3389_fimmu_2023_1199089
crossref_primary_10_1111_ddg_150_12891
crossref_primary_10_2217_fon_2019_0650
crossref_primary_10_1172_JCI128654
crossref_primary_10_1016_j_intimp_2022_109638
crossref_primary_10_1016_j_bbcan_2021_188577
crossref_primary_10_3389_fonc_2020_568059
crossref_primary_10_1016_j_nanoms_2021_12_001
crossref_primary_10_1186_s40425_016_0147_8
crossref_primary_10_1111_1759_7714_14001
crossref_primary_10_2147_OTT_S240655
crossref_primary_10_3389_fcell_2022_822187
crossref_primary_10_1016_j_bbrc_2015_12_100
crossref_primary_10_3390_cancers14215458
crossref_primary_10_1186_s13567_018_0543_9
crossref_primary_10_1007_s13311_017_0513_3
crossref_primary_10_1007_s11825_016_0111_5
crossref_primary_10_1007_s11739_025_03904_8
crossref_primary_10_1007_s13760_020_01282_w
crossref_primary_10_1080_14737140_2021_1882859
crossref_primary_10_1007_s40487_016_0016_0
crossref_primary_10_3390_cancers12123529
crossref_primary_10_3389_fphar_2022_908079
crossref_primary_10_1002_jlcr_4122
crossref_primary_10_1007_s00262_021_02864_0
crossref_primary_10_1007_s10147_016_0959_z
crossref_primary_10_1177_1176935117712520
crossref_primary_10_1080_14740338_2020_1764936
crossref_primary_10_1016_j_bbcan_2021_188593
crossref_primary_10_1111_dth_15184
crossref_primary_10_3389_fgene_2022_894865
crossref_primary_10_1016_j_drudis_2016_04_011
crossref_primary_10_3892_ijo_2025_5758
crossref_primary_10_1056_NEJMc1509268
crossref_primary_10_1097_PPO_0000000000000236
crossref_primary_10_3390_ijms25010676
crossref_primary_10_1186_s13075_022_02737_6
crossref_primary_10_1007_s12149_022_01782_0
crossref_primary_10_1053_j_gastro_2022_10_030
crossref_primary_10_1158_1078_0432_CCR_16_1821
crossref_primary_10_1007_s00117_017_0297_9
crossref_primary_10_1007_s10822_020_00306_0
crossref_primary_10_1093_jimmun_vkae007
crossref_primary_10_31083_j_ceog5010204
crossref_primary_10_1189_jlb_5RI0116_013RR
crossref_primary_10_3390_cancers9090115
crossref_primary_10_1016_j_jtbi_2021_110975
crossref_primary_10_1007_s00018_023_04946_x
crossref_primary_10_1097_GCO_0000000000000257
crossref_primary_10_3390_cancers15133348
crossref_primary_10_3233_HAB_210443
crossref_primary_10_3390_cancers17050817
crossref_primary_10_3390_cancers14153653
crossref_primary_10_1038_s41419_023_06391_x
crossref_primary_10_1038_modpathol_2017_86
crossref_primary_10_1016_j_mcp_2020_101601
crossref_primary_10_1371_journal_pone_0300789
crossref_primary_10_3390_ijms20092296
crossref_primary_10_3390_cancers14112782
crossref_primary_10_1007_s00280_022_04415_5
crossref_primary_10_1177_1536012119829986
crossref_primary_10_3390_jpm11080739
crossref_primary_10_1016_j_bios_2023_115644
crossref_primary_10_1016_j_steroids_2016_05_006
crossref_primary_10_1177_1758835918794628
crossref_primary_10_1016_j_ijpharm_2021_121027
crossref_primary_10_1007_s00428_018_2438_6
crossref_primary_10_3389_fimmu_2021_666137
crossref_primary_10_1038_modpathol_2017_79
crossref_primary_10_1245_s10434_020_08375_z
crossref_primary_10_3389_fphar_2022_1004821
crossref_primary_10_3389_fimmu_2021_610149
crossref_primary_10_1002_adfm_201604366
crossref_primary_10_3389_fimmu_2022_828386
crossref_primary_10_1038_s41525_018_0051_x
crossref_primary_10_1155_2021_9987376
crossref_primary_10_1186_s12967_023_03910_4
crossref_primary_10_2147_CMAR_S349442
crossref_primary_10_1097_CJI_0000000000000244
crossref_primary_10_1002_advs_202103677
crossref_primary_10_1038_s41379_019_0345_2
crossref_primary_10_1038_s41379_020_0567_3
crossref_primary_10_1111_bjh_16414
crossref_primary_10_1093_ajcp_aqx162
crossref_primary_10_1007_s11864_017_0492_y
crossref_primary_10_2217_imt_2019_0040
crossref_primary_10_1097_GCO_0000000000000596
crossref_primary_10_1634_theoncologist_2018_0470
crossref_primary_10_3389_fimmu_2020_578877
crossref_primary_10_1016_j_yexcr_2017_09_008
crossref_primary_10_3390_cells9030561
crossref_primary_10_1016_j_intimp_2020_107199
crossref_primary_10_12998_wjcc_v8_i3_624
crossref_primary_10_2217_fon_2021_0901
crossref_primary_10_3389_fimmu_2021_711433
crossref_primary_10_1158_2326_6066_CIR_19_0146
crossref_primary_10_1016_j_isci_2024_110634
crossref_primary_10_1634_theoncologist_2017_0354
crossref_primary_10_3390_ijms19041019
crossref_primary_10_1016_j_transproceed_2019_08_002
crossref_primary_10_1038_modpathol_2015_158
crossref_primary_10_1080_14740338_2021_1898584
crossref_primary_10_3390_biom6010003
crossref_primary_10_1016_j_medcle_2020_06_030
crossref_primary_10_1007_s00262_021_02900_z
crossref_primary_10_3389_fonc_2018_00054
crossref_primary_10_1136_jitc_2020_000656
crossref_primary_10_2217_fon_2019_0783
crossref_primary_10_1038_s41591_019_0374_x
crossref_primary_10_1080_2162402X_2017_1279777
crossref_primary_10_1111_dth_13250
ContentType Journal Article
Copyright Copyright © 2015 Elsevier Inc. All rights reserved.
Copyright_xml – notice: Copyright © 2015 Elsevier Inc. All rights reserved.
DBID CGR
CUY
CVF
ECM
EIF
NPM
7X8
DOI 10.1053/j.seminoncol.2015.05.013
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic
MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: 7X8
  name: MEDLINE - Academic
  url: https://search.proquest.com/medline
  sourceTypes: Aggregation Database
DeliveryMethod no_fulltext_linktorsrc
Discipline Medicine
EISSN 1532-8708
EndPage 600
ExternalDocumentID 26320063
Genre Review
Research Support, Non-U.S. Gov't
Journal Article
Research Support, N.I.H., Extramural
GrantInformation_xml – fundername: NCI NIH HHS
  grantid: R01 CA142779
– fundername: NCI NIH HHS
  grantid: R01CA142779
GroupedDBID ---
--K
.1-
.55
.FO
.GJ
0R~
123
1P~
3O-
4.4
457
4CK
53G
5RE
AAEDW
AALRI
AAQOH
AAQQT
AAQXK
AAWTL
AAXUO
ABFRF
ABJNI
ABOCM
ABUDA
ABWVN
ACGFO
ACRPL
ADBBV
ADMUD
ADNMO
AEFWE
AENEX
AEVXI
AFCTW
AFETI
AFFNX
AFJKZ
AFRHN
AFTJW
AGHFR
AGQPQ
AGRDE
AIGII
AITUG
AJUYK
ALMA_UNASSIGNED_HOLDINGS
AMRAJ
APXCP
ASPBG
AVWKF
AZFZN
CGR
CS3
CUY
CVF
DU5
EBS
ECM
EIF
EJD
F5P
FDB
FEDTE
FGOYB
GBLVA
HVGLF
HZ~
IH2
J5H
K-O
L7B
MJL
N4W
NPM
O9-
OC~
OO-
P2P
R2-
RIG
ROL
SEL
SES
SJN
TWZ
UDS
X7M
Z5R
ZGI
ZXP
7X8
ID FETCH-LOGICAL-c657t-4e60e5ee620db2443ee14a8de2eee031eed944c11d2e653af8c5f2f74ceb812
IEDL.DBID 7X8
ISICitedReferencesCount 250
ISICitedReferencesURI http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000360782200008&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
IngestDate Sun Aug 24 03:33:39 EDT 2025
Mon Jul 21 06:05:07 EDT 2025
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 4
Language English
License Copyright © 2015 Elsevier Inc. All rights reserved.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c657t-4e60e5ee620db2443ee14a8de2eee031eed944c11d2e653af8c5f2f74ceb812
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-2
OpenAccessLink http://doi.org/10.1053/j.seminoncol.2015.05.013
PMID 26320063
PQID 1708896435
PQPubID 23479
PageCount 14
ParticipantIDs proquest_miscellaneous_1708896435
pubmed_primary_26320063
PublicationCentury 2000
PublicationDate 2015-08-01
PublicationDateYYYYMMDD 2015-08-01
PublicationDate_xml – month: 08
  year: 2015
  text: 2015-08-01
  day: 01
PublicationDecade 2010
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle Seminars in oncology
PublicationTitleAlternate Semin Oncol
PublicationYear 2015
References 25384885 - Oncology (Williston Park). 2014 Nov;28 Suppl 3:30-8
25428505 - Nature. 2014 Nov 27;515(7528):568-71
24608200 - Ann Oncol. 2014 Aug;25(8):1544-50
22437870 - Nat Rev Cancer. 2012 Apr;12(4):252-64
24590637 - J Clin Oncol. 2014 Apr 1;32(10):1020-30
23341518 - J Clin Oncol. 2013 Mar 1;31(7):860-7
24145345 - J Clin Oncol. 2013 Dec 1;31(34):4311-8
22679113 - J Natl Compr Canc Netw. 2012 Jun 1;10(6):690-3
22658127 - N Engl J Med. 2012 Jun 28;366(26):2443-54
23253225 - Expert Rev Anticancer Ther. 2012 Dec;12(12):1597-611
23288508 - Cancer Res. 2013 Mar 15;73(6):1733-41
21710841 - Oncology (Williston Park). 2011 Apr 30;25(5):427-8
25428503 - Nature. 2014 Nov 27;515(7528):558-62
25524312 - Clin Cancer Res. 2015 Feb 15;21(4):712-20
23724846 - N Engl J Med. 2013 Jul 11;369(2):134-44
24714771 - Clin Cancer Res. 2014 Oct 1;20(19):5064-74
12529460 - N Engl J Med. 2003 Jan 16;348(3):203-13
19825956 - Clin Cancer Res. 2009 Oct 15;15(20):6341-7
25452452 - J Clin Oncol. 2015 May 1;33(13):1430-7
20818862 - N Engl J Med. 2010 Jul 29;363(5):411-22
22658128 - N Engl J Med. 2012 Jun 28;366(26):2455-65
24658839 - Cancer Immunol Immunother. 2014 Jun;63(6):545-57
25409260 - N Engl J Med. 2014 Dec 4;371(23):2189-99
22186141 - Cancer Res. 2012 Feb 15;72(4):917-27
25428504 - Nature. 2014 Nov 27;515(7528):563-7
25482239 - N Engl J Med. 2015 Jan 22;372(4):311-9
23756627 - Breast Cancer Res Treat. 2013 Jun;139(3):667-76
25399552 - N Engl J Med. 2015 Jan 22;372(4):320-30
20628145 - Blood. 2010 Oct 28;116(17):3268-77
25034862 - Lancet. 2014 Sep 20;384(9948):1109-17
25358689 - Cancer Discov. 2015 Jan;5(1):43-51
17159987 - Nat Med. 2007 Jan;13(1):84-8
24831977 - Lancet Oncol. 2014 Jun;15(7):700-12
24842267 - Breast Cancer Res Treat. 2014 Jul;146(1):15-24
17360651 - Proc Natl Acad Sci U S A. 2007 Feb 27;104(9):3360-5
23169436 - Clin Cancer Res. 2013 Jan 15;19(2):462-8
23724867 - N Engl J Med. 2013 Jul 11;369(2):122-33
22461641 - Sci Transl Med. 2012 Mar 28;4(127):127ra37
22547591 - J Clin Oncol. 2012 Jun 10;30(17):2055-62
20516446 - J Clin Oncol. 2010 Jul 1;28(19):3167-75
References_xml – reference: 25399552 - N Engl J Med. 2015 Jan 22;372(4):320-30
– reference: 22437870 - Nat Rev Cancer. 2012 Apr;12(4):252-64
– reference: 25428503 - Nature. 2014 Nov 27;515(7528):558-62
– reference: 25428505 - Nature. 2014 Nov 27;515(7528):568-71
– reference: 20818862 - N Engl J Med. 2010 Jul 29;363(5):411-22
– reference: 20628145 - Blood. 2010 Oct 28;116(17):3268-77
– reference: 24714771 - Clin Cancer Res. 2014 Oct 1;20(19):5064-74
– reference: 24590637 - J Clin Oncol. 2014 Apr 1;32(10):1020-30
– reference: 25384885 - Oncology (Williston Park). 2014 Nov;28 Suppl 3:30-8
– reference: 25452452 - J Clin Oncol. 2015 May 1;33(13):1430-7
– reference: 22679113 - J Natl Compr Canc Netw. 2012 Jun 1;10(6):690-3
– reference: 23169436 - Clin Cancer Res. 2013 Jan 15;19(2):462-8
– reference: 23288508 - Cancer Res. 2013 Mar 15;73(6):1733-41
– reference: 23724867 - N Engl J Med. 2013 Jul 11;369(2):122-33
– reference: 25034862 - Lancet. 2014 Sep 20;384(9948):1109-17
– reference: 23253225 - Expert Rev Anticancer Ther. 2012 Dec;12(12):1597-611
– reference: 24608200 - Ann Oncol. 2014 Aug;25(8):1544-50
– reference: 25524312 - Clin Cancer Res. 2015 Feb 15;21(4):712-20
– reference: 23341518 - J Clin Oncol. 2013 Mar 1;31(7):860-7
– reference: 25482239 - N Engl J Med. 2015 Jan 22;372(4):311-9
– reference: 20516446 - J Clin Oncol. 2010 Jul 1;28(19):3167-75
– reference: 23756627 - Breast Cancer Res Treat. 2013 Jun;139(3):667-76
– reference: 24658839 - Cancer Immunol Immunother. 2014 Jun;63(6):545-57
– reference: 19825956 - Clin Cancer Res. 2009 Oct 15;15(20):6341-7
– reference: 22186141 - Cancer Res. 2012 Feb 15;72(4):917-27
– reference: 24145345 - J Clin Oncol. 2013 Dec 1;31(34):4311-8
– reference: 25428504 - Nature. 2014 Nov 27;515(7528):563-7
– reference: 22658127 - N Engl J Med. 2012 Jun 28;366(26):2443-54
– reference: 25409260 - N Engl J Med. 2014 Dec 4;371(23):2189-99
– reference: 17360651 - Proc Natl Acad Sci U S A. 2007 Feb 27;104(9):3360-5
– reference: 22547591 - J Clin Oncol. 2012 Jun 10;30(17):2055-62
– reference: 22461641 - Sci Transl Med. 2012 Mar 28;4(127):127ra37
– reference: 25358689 - Cancer Discov. 2015 Jan;5(1):43-51
– reference: 17159987 - Nat Med. 2007 Jan;13(1):84-8
– reference: 22658128 - N Engl J Med. 2012 Jun 28;366(26):2455-65
– reference: 23724846 - N Engl J Med. 2013 Jul 11;369(2):134-44
– reference: 24831977 - Lancet Oncol. 2014 Jun;15(7):700-12
– reference: 24842267 - Breast Cancer Res Treat. 2014 Jul;146(1):15-24
– reference: 21710841 - Oncology (Williston Park). 2011 Apr 30;25(5):427-8
– reference: 12529460 - N Engl J Med. 2003 Jan 16;348(3):203-13
SSID ssj0021722
Score 2.5741272
SecondaryResourceType review_article
Snippet The PD-1 pathway, comprising the immune cell co-receptor Programmed Death 1 (PD-1) and its ligands, PD-L1 (B7-H1) and PD-L2 (B7-DC), mediates local...
SourceID proquest
pubmed
SourceType Aggregation Database
Index Database
StartPage 587
SubjectTerms Antineoplastic Agents - therapeutic use
B7-H1 Antigen - antagonists & inhibitors
Biomarkers, Tumor - metabolism
Humans
Immunosuppression - methods
Neoplasms - drug therapy
Neoplasms - metabolism
Programmed Cell Death 1 Receptor - antagonists & inhibitors
Tumor Microenvironment - drug effects
Title Antagonists of PD-1 and PD-L1 in Cancer Treatment
URI https://www.ncbi.nlm.nih.gov/pubmed/26320063
https://www.proquest.com/docview/1708896435
Volume 42
WOSCitedRecordID wos000360782200008&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText
inHoldings 1
isFullTextHit
isPrint
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LS8NAEF7Uinjx_agvVvAamk32kZykVIuHthTsobew3cxCD6a1qf5-Z5pET4LgJSyBwDLzZR47384w9uBSiPNwpgJtY0pQQgisxaw1gTA2GEEbVzVJGpjRKJlO03F94FbWtMrGJm4Mdb5wdEbeEYYIOeg_1ePyPaCpUVRdrUdobLNWjKEModpMv6sINHupYe8g1jp0i_ttjlk1iphIXarq2Rn_HlxunEz_8L_bO2IHdXjJuxUejtkWFCdsb1gX0E-Z6BZUhqJ2uSVfeD5-CgS3RU6LgeDzgvcIBis-aQjoZ-y1_zzpvQT11ITAaWXWgQQdggLQUZjP0HnHAELaJIcIABUg0CmmUjoh8gi0iq1PnPKRN9LBDL39OdtBCcEl4zOQkOg8gUhaqX2aWAXGo233Vkf4ts3uG1FkiEkqNNgCFh9l9iOMNruo5Jktq-YZGfWHp7jo6g9fX7N9UlPFt7thLY9_JNyyXfe5nperu42y8TkaD78AHFS0dw
linkProvider ProQuest
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Antagonists+of+PD-1+and+PD-L1+in+Cancer+Treatment&rft.jtitle=Seminars+in+oncology&rft.au=Lipson%2C+Evan+J&rft.au=Forde%2C+Patrick+M&rft.au=Hammers%2C+Hans-Joerg&rft.au=Emens%2C+Leisha+A&rft.date=2015-08-01&rft.eissn=1532-8708&rft.volume=42&rft.issue=4&rft.spage=587&rft_id=info:doi/10.1053%2Fj.seminoncol.2015.05.013&rft_id=info%3Apmid%2F26320063&rft_id=info%3Apmid%2F26320063&rft.externalDocID=26320063